The company uses artificial intelligence to generate RNA datasets that can be used for drug discovery. Previously, the company had raised $7 million in a seed financing round, according to a Jan. 25 Atomic AI news release.
Playground Global led the financing.
“To create effective and safer small molecules against undruggable diseases, there is a significant need to develop tools that can accurately predict 3D RNA structures,” Atomic AI founder and CEO Raphael Townshend, PhD, said. “Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology. We are creating an entirely new field of drug discovery.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
